Torrent Pharma enters into agreement with Dr Reddy's Laboratories

27 May 2022 Evaluate

Torrent Pharmaceuticals has entered into agreement with Dr Reddy's Laboratories to acquire four of its brands -- Styptovit-E, Finast, Finast-T and Dynapress.

As per the terms of the definitive agreement, Torrent Pharma will take over the manufacturing, marketing and distribution of these brands in India. The complete integration and transition of the brands are expected to be completed by June 2022.

Styptovit-E, a gynaecology product with an estimated market size of Rs 500 crore (AIOCD data set), will further strengthen the company's presence in the segment. The acquisition of 'Finast', 'Finast-T', and 'Dynapress', which are used in the treatment of Benign Prostatic Hyperplasia (BPH), will aid the drug firm in strengthening its presence in the urology segment.

Torrent Pharmaceuticals is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharma Share Price

3207.70 5.55 (0.17%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.